Literature DB >> 6976355

Characterization of the defect in activation of factor IX Chapel Hill by human factor XIa.

K M Braunstein, C M Noyes, M J Griffith, R L Lundblad, H R Roberts.   

Abstract

Factor IXChapel Hill (Factor IXCH), an abnormal Factor IX molecule isolated from the plasma of a patient with mild hemophilia B, has previously been shown to exhibit delayed activation by Factor XIa and calcium. In this study, we have found that Factor IXCH is cleaved upon incubation with human Factor XIa and calcium; however, cleavage of this protein is not observed by sodium dodecyl sulfate (SDS) polyacrylamide gel electrophoresis under nonreducing conditions. Under reducing conditions, the rate of disappearance of the zymogen parallels both the appearance of the heavy chain and the generation of clotting activity. In addition, a protein band that migrates with an apparent molecular weight of 45,000 also increases in parallel with clotting activity. Factor IXCH and normal Factor IX (Factor IXN), after incubation with Factor XIa and calcium, were subjected to amino terminal sequence analysis. Activated Factor IXN is cleaved at an arginine-alanine (Arg-Ala) bond and an arginine-valine (Arg-Val) bond as demonstrated by formation of the three amino terminal sequences corresponding to the amino terminal of the light chain, heavy chain, and activation peptide. However, activated Factor IXCH has only two amino terminal sequences, corresponding to the original amino terminal sequence and the heavy chain (formed by cleavage at the Arg-Val bond). It is concluded that the major defect in Factor IXCH is the inability of Factor XIa to cleave the Arg-Ala bond at a significant rate. The rate of formation of clotting activity of Factor IXCH is approximately 60% of the rate of formation of clotting activity of Factor IXN. The specific clotting activity of activated Factor IXCH is between 20 and 33% of activated Factor IXN.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6976355      PMCID: PMC370943          DOI: 10.1172/jci110393

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  22 in total

1.  THE INTERACTION OF CONTACT PRODUCT AND FACTOR IX.

Authors:  A D CATTAN; K W DENSON
Journal:  Thromb Diath Haemorrh       Date:  1964-04-15

2.  THE IDENTIFICATION AND SYNTHESIS OF ACTIVATED PLASMA THROMBOPLASTIN COMPONENT (PTC').

Authors:  S SCHIFFMAN; S I RAPAPORT; M J PATCH
Journal:  Blood       Date:  1963-12       Impact factor: 22.113

3.  THE ACTIVATION AND CONSUMPTION OF FACTOR IX.

Authors:  H L NOSSEL
Journal:  Thromb Diath Haemorrh       Date:  1964-12-31

4.  The formation of intermediate product I in a purified system. The role of factor IX or its precursor and of a Hageman factor-PTA fraction.

Authors:  E T YIN; F DUCKERT
Journal:  Thromb Diath Haemorrh       Date:  1961-09-01

5.  The chromatography of growth hormone on cellulose derivatives.

Authors:  S ELLIS; M E SIMPSON
Journal:  J Biol Chem       Date:  1956-06       Impact factor: 5.157

6.  Haemophilia Bm: a new type of factor-IX deficiency.

Authors:  C Hougie; J J Twomey
Journal:  Lancet       Date:  1967-04-01       Impact factor: 79.321

7.  The reliability of molecular weight determinations by dodecyl sulfate-polyacrylamide gel electrophoresis.

Authors:  K Weber; M Osborn
Journal:  J Biol Chem       Date:  1969-08-25       Impact factor: 5.157

8.  Kinetics of factor IX activation via the extrinsic pathway. Dependence of Km on tissue factor.

Authors:  M Zur; Y Nemerson
Journal:  J Biol Chem       Date:  1980-06-25       Impact factor: 5.157

9.  A protein sequenator.

Authors:  P Edman; G Begg
Journal:  Eur J Biochem       Date:  1967-03

10.  Comparison of amino acid sequence of bovine coagulation Factor IX (Christmas Factor) with that of other vitamin K-dependent plasma proteins.

Authors:  K Katayama; L H Ericsson; D L Enfield; K A Walsh; H Neurath; E W Davie; K Titani
Journal:  Proc Natl Acad Sci U S A       Date:  1979-10       Impact factor: 11.205

View more
  4 in total

1.  Identification of the molecular defect in factor IX Chapel Hill: substitution of histidine for arginine at position 145.

Authors:  C M Noyes; M J Griffith; H R Roberts; R L Lundblad
Journal:  Proc Natl Acad Sci U S A       Date:  1983-07       Impact factor: 11.205

2.  Characterization of the clotting activities of structurally different forms of activated factor IX. Enzymatic properties of normal human factor IXa alpha, factor IXa beta, and activated factor IX Chapel Hill.

Authors:  M J Griffith; L Breitkreutz; H Trapp; E Briet; C M Noyes; R L Lundblad; H R Roberts
Journal:  J Clin Invest       Date:  1985-01       Impact factor: 14.808

3.  Characterization of three abnormal factor IX variants (Bm Lake Elsinore, Long Beach, and Los Angeles) of hemophilia-B. Evidence for defects affecting the latent catalytic site.

Authors:  P Usharani; B J Warn-Cramer; C K Kasper; S P Bajaj
Journal:  J Clin Invest       Date:  1985-01       Impact factor: 14.808

4.  Regulation of factor IXa in vitro in human and mouse plasma and in vivo in the mouse. Role of the endothelium and the plasma proteinase inhibitors.

Authors:  H E Fuchs; H G Trapp; M J Griffith; H R Roberts; S V Pizzo
Journal:  J Clin Invest       Date:  1984-06       Impact factor: 14.808

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.